科伦博泰生物：与宜联生物达成和解后后者6款ADC管线收入需按比例分成

Core Viewpoint - The company has reached a settlement agreement with Suzhou Yilian Biopharmaceutical Co., Ltd. and other parties to resolve several disputes, including criminal accusations and civil lawsuits related to business secrets and company interests [1] Group 1: Settlement Agreement - The settlement aims to save time and costs associated with legal proceedings [1] - Yilian Biopharmaceutical is required to share a certain percentage of revenue and net profit from specific products (YL201, YL202, YL211, YL212, YL221, and YL222) generated before and after the effective date of the settlement [1] - The board believes that the settlement will not have a significant adverse impact on the company's financial condition and operations [1]